Evidence map›Paper›PMID 39224007›Full record

ArticleAlimentary pharmacology & therapeutics2024

Editorial: Cardiometabolic criteria matters in MASLD-Authors' reply.

Nobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Nobuharu TamakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.ORCID 0000-0003-4634-6616
Takefumi KimuraDivision of Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.ORCID 0000-0002-1481-1029
Shun-Ichi WakabayashiDivision of Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.
Takeji UmemuraDivision of Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Rohit LoombaDivision of Gastroenterology and Hepatology, Department of Medicine, MASLD Research Center, University of California San Deigo, La Jolla, California, USA.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
Tissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EVANS, RONALD M · 2020 to 2024
$12.2M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
HIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7M
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4M
San Diego Cirrhosis Clinical Research NetworkU01DK130190 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2021 to 2026
$2.3M
Non-invasive screening of diabetics for advanced fibrosis due to NAFLDR01DK124318 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2022
$1.7M
Japan Agency for Medical Research and Development JP24fk0210104Japan Agency for Medical Research and Development JP24fk0210111Japan Agency for Medical Research and Development JP24fk0210113Japan Agency for Medical Research and Development JP24fk0210123Japan Agency for Medical Research and Development JP24fk0210125John C Martin Foundation RP124Ministry of Health, Labour and Welfare 23HC2001Ministry of Health, Labour and Welfare 23HC2002Ministry of Health, Labour and Welfare 23HC2003NCATS NIH HHS 5UL1TR001442NCATS NIH HHS UL1 TR001442NHLBI NIH HHS P01 HL147835NHLBI NIH HHS P01HL147835NIDDK NIH HHS P30 DK120515NIDDK NIH HHS P30DK120515NIDDK NIH HHS R01 DK106419NIDDK NIH HHS R01DK106419NIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01DK121378NIDDK NIH HHS R01 DK124318NIDDK NIH HHS R01DK124318NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01DK061734NIDDK NIH HHS U01 DK130190NIDDK NIH HHS U01DK130190
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiovascular DiseasesHumansMetabolic Syndrome

Identifiers

PMID39224007
PMCPMC12393154

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.